Vascular endothelial growth factor expression in malignant melanoma: Prognostic versus diagnostic usefulness

Modern Pathology

Volumn 12, Issue 8, 1999, Pages 770-774

  Bayer Garner, Ilene B ^a   Hough Jr , Aubrey J ^a   Smoller, Bruce R ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Benign melanocytic lesions; Dysplastic nevi; Malignant melanoma; Vascular endothelial growth factor

Indexed keywords

FORMALDEHYDE; PARAFFIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLUE NEVUS; CANCER GROWTH; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; JUVENILE MELANOMA; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

DIAGNOSIS, DIFFERENTIAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MALE; MELANOMA; MIDDLE AGED; NEVUS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032839043     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Salven P, Heikkla P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997;76:930-4.
2. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991;174:1275-9.
3. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo K, Manseau EJ, et al. Expression of vascular permeability factor / vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996;56:172-81.
4. Gitay-Goren H, Halaban R, Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 1993;190:702-8.
5. Potgens AJG, Lubsen NH, van Altena MC, Schoenmakers JGG, Ruiter DJ, de Waal RMW. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995;146: 197-209.
6. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov DC, Armellino D, Gospodarwicz D, et al. Identification of the KDR tryosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187: 1579-86.
7. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91.
8. Lui B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ, et al. Melanoma cell lines express VEGF receptors KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 1995;217:721-7.
9. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, et al. In oesophageal squamous cell carcinoma, vascular endothelial growth factor is associated with p53 mutation, advanced stage, and poor prognosis. Br J Cancer 1998;77:1704-9.
10. McKee PH. Melanocytic nevi and malignant melanoma. In: McKee PH, editor. Pathology of the skin with clinical correlations. 2nd ed. London: Times Mirror; 1996. p. 13-38.
11. Clark WH Jr, Elder DE, Guerry D 4th, Braitman LE, Track BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893-904.
12. Rhodes WR, Mihm MC, Weinstock MA. Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol 1989;2:306-19.
13. Wienstock MA, Barnhill RL, Rhodes AR, Brodsky GL, Dysplastic Nevus Panel. Reliability of the histopathologic diagnosis of melanocytic dysplasia. Arch Dermatol 1997;133:953-8.
14. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor / vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93: 14765-70.